New Corporate Member
IPC is pleased to welcome AnaptysBio as a Bronze Level Corporate Member!
Tuesday, May 3, 2022
Psoriasis News
THE LATEST FROM IPC, INDUSTRY AND OTHERS
Results
Newest IPC Councilors
Three councilors join the group of IPC experts who are working to advance knowledge and enhance the care psoriasis patients around the world.
Monday, April 18, 2022
Focus on Psoriasis: A Report from the 2022 American Academy of Dermatology (AAD) Annual Meeting
The 2022 American Academy of Dermatology (AAD) Annual Meeting was held Thursday, March 24 – Tuesday, March 29 in Boston, Massachusetts. The program was packed with sessions showcasing the latest innovations in dermatology and venereology. Grace Hile, MD, has written a congress report with summaries of eleven psoriasis-focused presentations. You can download the full report or read on for a brief look at some of the highlights.
Thursday, April 14, 2022
Commentary: IFN-k is a rheostat for development of psoriasiform inflammation
IPC Councilor, Carlo Pincelli, MD, shares his expert opinion on innovative research that connects insights into immunopathogenesis with genetics and modes of action of treatments.
Tuesday, April 12, 2022
Amgen Announces New Otezla (Apremilast) Data
Amgen presents new data on the efficacy of apremilast in patients with mild to moderate plaque psoriasis and in patients with palmoplantar pustulosis.
Tuesday, April 5, 2022
Janssen Initiates First-of-its-kind Clinical Study to Bridge Critical Gaps in Care for People of Color With Moderate to Severe Plaque Psoriasis
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the initiation of VISIBLE. VISIBLE is a first-of-its-kind, large-scale prospective clinical study dedicated to generating key disease insights among Black, Hispanic, Asian, Indigenous, and other people of color.
Monday, April 4, 2022
Focus on Psoriasis: A Report from the 2021 Hybrid Gene to Clinic Congress
The Psoriasis: from Gene to Clinic International Congress provides a forum for psoriasis experts from around the world to present and discuss cutting-edge issues. You can download the full report or read a summary of some of the highlights.
Monday, February 21, 2022
Commentary: Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study
A research group led by Catherine Smith from St John’s Institute of Dermatology described humoral and cellular immunity.
Tuesday, January 25, 2022
Latin American Case Series
It is not fully understood the impact that COVID-19 has on psoriasis patients.
Wednesday, January 19, 2022
New corporate member
IPC is pleased to welcome Arcutis Biotherapeutics, Inc. as a 2022 Bronze Level Corporate Member.
Tuesday, January 18, 2022
New board members
Meet the three new key opinion leaders who have been elected to join our board.
Wednesday, January 12, 2022
New board officers
IPC’s newly appointed appointed officers take their roles beginning January 1, 2022.
Wednesday, January 12, 2022
Subscribe to the IPC Newsletter
We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.
